Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.
Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Yi JH, et al. Among authors: ahn hk. Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. Cancer Res Treat. 2016. PMID: 26323641 Free PMC article.
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR. Lim SM, et al. Among authors: ahn mj, ahn hk. Cancer Res Treat. 2019 Jan;51(1):300-312. doi: 10.4143/crt.2018.012. Epub 2018 May 9. Cancer Res Treat. 2019. PMID: 29747488 Free PMC article.
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: ahn js, ahn hk. Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24. Lancet Oncol. 2019. PMID: 31668850 Clinical Trial.
282 results